Ascletis Advances in Clinical Development with ASC36
Ascletis Pharma Inc. is making significant strides towards effective treatments for obesity with the selection of ASC36 oral tablets as their key candidate. This development highlights the company's innovative use of Peptide Oral Transport Enhancement Technology (POTENT), which has shown promising results in bioavailability during preclinical studies.
Promising Results from Preclinical Studies
In non-human primate studies, ASC36 oral tablets achieved an impressive absolute oral bioavailability ranging from 6% to 8% when dosed consistently. This substantial bioavailability indicates that the drug is effectively absorbed, setting a solid foundation for future human trials.
Moreover, these studies revealed that ASC36 not only led to a significant mean body weight reduction—up to 13.2% after just one week of daily administration—but also decreased food intake notably. Such results are pivotal as they suggest ASC36 could be a powerful tool against obesity.
Comparative Efficacy in Obesity Models
Further examination in a diet-induced obese rat model showcased the effectiveness of ASC36 oral tablets. When compared to other treatments like eloralintide and petrelintide, ASC36 demonstrated a remarkable 32% and 91% greater reduction in relative body weight, respectively. These compelling figures underline the potential of ASC36 to surpass existing therapies.
What sets ASC36 apart is not only its efficacy but also its delivery method, which could enable lower dosing compared to recently approved treatments, thus enhancing manufacturing scalability for wider availability.
Regulatory Plans and Timeline
Looking ahead, Ascletis plans to submit an Investigational New Drug Application (IND) for ASC36 to the U.S. Food and Drug Administration (FDA), expected in the near future. This submission marks a crucial step in advancing ASC36 towards clinical development and eventual patient accessibility.
Innovation through Proprietary Technology
ASC36 is a product of Ascletis' commitment to innovative drug development through its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) process. With the integration of advanced technologies like the Ultra-Long-Acting Platform (ULAP) and POTENT, the company is crafting a robust portfolio of drug candidates tailored to meet the diverse needs of patients suffering from metabolic issues.
Insights from Company Leadership
Dr. Jinzi Jason Wu, Founder, Chairman and CEO of Ascletis, emphasizes the strategic importance of ASC36. He notes its vital role among their pipeline, which includes an array of amylin drug candidates—demonstrating their dedication to addressing the complexities of obesity and related metabolic diseases.
Through their unique technological capabilities, Ascletis is not just developing drugs, but crafting comprehensive solutions aimed at transforming the treatment landscape for obesity.
About Ascletis Pharma Inc.
Ascletis Pharma Inc. operates as a fully integrated biotechnology company focused on creating cutting-edge therapeutics to combat metabolic diseases. The company utilizes its revolutionary technologies, including AISBDD and ULAP, to develop a range of drug candidates targeting various forms of obesity. Their portfolio features notable projects like ASC30, ASC36, and ASC35, setting the stage for progressive advancements in patient care.
Frequently Asked Questions
What is ASC36 and what condition does it aim to treat?
ASC36 is an oral amylin receptor peptide agonist that Ascletis is developing to treat obesity, aiming for effective weight management.
How does ASC36 show effectiveness in studies?
In studies, ASC36 has been shown to significantly reduce body weight and food intake in both non-human primates and diet-induced obese rat models.
What advantages does Ascletis' POTENT technology provide?
POTENT technology enhances oral bioavailability of peptides, which is critical for effective dosing and application in treatments like ASC36.
When is the IND application planned for ASC36?
Ascletis aims to submit the IND application to the FDA in the near future to commence clinical trials for ASC36.
What role does innovation play in Ascletis' drug development?
Ascletis employs advanced technologies, including AI and structure-based design, to create innovative therapeutics tailored to complex health challenges.
